Background: Bone marrow involvement (BMI) appears to be a rare event in patients (PTS) with germ cell tumors (GCT). Results: Three PTS with GCT and metastatic BMI have been observed. Two PTS were classified as clinical stage (CS) I at initial diagnosis, one PT had advanced disease, constituting a prognostically bad group. All three PTS had LDH levels above 1,000 U/l at detection of BMI. Two of 3 PTS showed severe thrombocyto-penia ( < 20,000/μl) at the time of BMI diagnosis. The increase of the specific tumor markers AFP or ß-HCG was only marginal prior to the detection of BMI. Two PTS reached a complete remission after treatment with aggressive cisplatinum-based chemotherapy (CTX), but ultimately relapsed in the bone marrow and died of progressive disease. One PT died due to thrombocytopenia and hyperfibrinolysis during the primary episode of BMI. Conclusion: The incidence of metastatic BMI in PTS with advanced GCT according to results of different treatment centers was 4 in 329 (1.2%). Clinically, bone marrow biopsies should be considered in PTS with prolonged thrombocytopenia after chemotherapy, especially in cases of elevated LDH levels.

Keywords:
Malignant germ cell tumors, Bone marrow involvement, Prognosis Chemotherapy
This content is only available via PDF.
© 1992 S. Karger AG, Basel
1992
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.